Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>The company operates a diversified portfolio of sterile liquid products across six therapeutic segments, with a strong domestic presence and expanding global reach, ensuring consistent revenue streams. </li>
<li>Proceeds from the IPO will fund the establishment of two new sterile manufacturing lines, significantly enhancing SteriPort and SVP capacities, expected to drive growth in FY26-27. </li>
<li>While the IPO valuation appears elevated at 46x FY25earnings, the company’s debt reduction and expanded capacity should lead to moderated multiples.</li>
</ul>


The company operates a diversified portfolio of sterile liquid products across six therapeutic segments, with a strong domestic presence and expanding global reach, ensuring consistent revenue streams. 
Proceeds from the IPO will fund the establishment of two new sterile manufacturing lines, significantly enhancing SteriPort and SVP capacities, expected to drive growth in FY26-27. 
While the IPO valuation appears elevated at 46x FY25earnings, the company’s debt reduction and expanded capacity should lead to moderated multiples.


The Beat Ideas: Amanta Healthcare IPO - Navigating Growth in the Sterile Pharma Space.

India

Amanta Healthcare is a pharmaceutical company that specializes in developing, manufacturing, and marketing a diverse range of sterile liquid products, including parenteral products, packaged using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology. They produce large volume parenterals (LVPs) and small volume parenterals (SVPs) across six therapeutic segments, and also manufacture medical devices. The company is headquartered in Ahmedabad, Gujarat, India, and was incorporated on December 21, 1994.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Amanta Healthcare (AMANTA IN)

The Beat Ideas: Amanta Healthcare IPO - Navigating Growth in the Sterile Pharma Space.

Company with diverse sterile liquid products portfolio, strong domestic presence & global reach, plans to use IPO proceeds for new manufacturing...

Nimish Maheshwari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

The Beat Ideas: Amanta Healthcare IPO - Navigating Growth in the Sterile Pharma Space.

​Company with diverse sterile liquid products portfolio, strong domestic presence & global reach, plans to use IPO proceeds for new manufacturing...

Nimish Maheshwari

Company with diverse sterile liquid products portfolio, strong domestic presence & global reach, plans to use IPO proceeds for new manufacturing...